Noopept tab 10mg # 50

Dosage form

Pills

Structure

ethyl ester of N-phenylacetyl-L-prolylglycine (noopept®) 10 mg

Excipients: microcrystalline cellulose, lactose (milk sugar), potato starch, povidone, magnesium stearate.

pharmachologic effect

Nootropic drug.

It has a nootropic and neuroprotective effect.

Improves learning ability, memory, acting on all phases of the process: initial information processing, consolidation, extraction.

Prevents the development of amnesia caused by electroshock, blockade of central cholinergic structures, glutamatergic receptor systems, deprivation of the paradoxical phase of sleep.

The neuroprotective effect of the drug is manifested in an increase in the resistance of the brain tissue to damaging influences (trauma, hypoxia, electroconvulsive or toxic effects) and in weakening the degree of damage to brain neurons.

The drug reduces the volume of the focus in the thrombotic model of stroke and prevents the death of neurons in the tissue culture of the cerebral cortex and cerebellum, exposed to neurotoxic concentrations of glutamate, free radical oxygen.

Noopept® has an antioxidant effect.

There is an antagonistic effect on the effects of excess calcium.

Improves the rheological properties of blood, having antiplatelet, fibrinolytic, anticoagulant properties.

The nootropic action of the drug is associated with the formation of cycloprolylglycine, which is similar in structure to an endogenous cyclic dipeptide with antiamnestic activity, as well as with the presence of a cholinopositive action.

Noopept® increases the amplitude of the transcallosal response, facilitating associative connections between the cerebral hemispheres at the level of cortical structures.

Noopept® promotes the restoration of memory and other cognitive functions impaired as a result of damaging influences - brain trauma, local and global ischemia, prenatal injuries (alcohol, hypoxia).

The therapeutic effect of the drug in patients with organic diseases of the central nervous system is manifested from 5-7 days of treatment.

Initially, anxiolytic and mild stimulating effects are realized, manifested in a decrease or disappearance of anxiety, increased irritability, affective lability, and sleep disturbances.

After 14-20 days of therapy, a positive effect of the drug on cognitive functions, attention and memory parameters is revealed.

Noopept® has a vegetative-normalizing effect, helps to reduce headaches, orthostatic disorders, and tachycardia.

Noopept® does not accumulate in the body, does not cause drug dependence.

Withdrawal of the drug is not observed withdrawal syndrome.

Noopept® does not have a damaging effect on internal organs, does not lead to a change in hematological and biochemical parameters, does not have an immunotoxic, teratogenic effect, does not exhibit mutagenic properties.

Pharmacokinetics

Suction

Absorbed from the gastrointestinal tract.

It is absorbed unchanged into the systemic circulation.

Cmax is reached on average after 15 minutes.

Bioavailability - 99.7%.

Distribution

Penetrates the BBB.

It is determined in the brain in higher concentrations than in the blood.

Metabolism and excretion

The drug is partially retained unchanged, partially metabolized to form phenylacetic acid, phenylacetylproline and cycloprolylglycine.

T1 / 2 - 0.38 h.

Side effects

Possibly: allergic reactions.

In patients with arterial hypertension, mainly of severe degree, while taking the drug, an increase in blood pressure may be observed.

Selling features

Available without a prescription

Special conditions

The patient should be informed that if it is necessary to increase the dose of the drug (up to 30 mg /), with prolonged use, as well as with simultaneous use with other drugs, the appearance of adverse reactions or worsening of the condition, consult a doctor.

Indications

Impaired memory, attention, other

Name ENG

NOOPEPT

Clinical and pharmacological group

Nootropic drug

ATX code

Other psychostimulants and nootropic drugs

Dosage

10mg

Structure

ethyl ester of N-phenylacetyl-L-prolylglycine (noopept®) 10 mg.

Excipients: microcrystalline cellulose, lactose (milk sugar), potato starch, povidone, magnesium stearate.

Indications

Impaired memory, attention, other cognitive functions and emotionally labile disorders, incl.

in elderly patients with the following conditions and diseases:

consequences of traumatic brain injury

post-concussion syndrome

cerebrovascular insufficiency (encephalopathy of various origins)

asthenic disorders

other conditions with signs of decreased intellectual productivity.

INN / Active ingredient

N-phenylacetyl-L-prolylglycine ethyl ester (noopept®)

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

Contraindications

Hypersensitivity to drug components

lactase deficiency, lactose intolerance, glucose-galactose malabsorption

severe violations of liver and kidney function

pregnancy

lactation period

age up to 18 years.

Specifications

Scope of the medicinal product

Neurology, psychiatry

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

fifty

Minimum age from

18 years

Way of introduction

Through the mouth

Vacation conditions

Without recipe

The amount of the dosage form in the primary package

25 pcs.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Nootropic agent

Anatomical and therapeutic characteristics

N06BX Other psychostimulants and nootropics

Dosage form

Pills

Dosage (volume) of the substance in the preparation

10 mg

Expiration date in days

1095

Package weight, g

twenty

Category

:

Mental strain

,

Memory impairment

,

Neuroprotective agents

,

Nootropic drugs

Mode of application

:

Noopept® is administered orally, after a meal.

< br> The drug is prescribed in an initial dose of 20 mg - 10 mg in 2 divided doses (morning and afternoon).

With insufficient effectiveness of therapy and with good tolerance of the drug, the dose is increased to 30 mg - 10 mg in 3 divided doses during the day.

< br> You should not take the drug later than 18 hours. < br> The duration of the course of treatment is 1.5-3 months.

A second course of treatment, if necessary, can be carried out after 1 month.

Information on technical characteristics, delivery set, country of manufacture